Eva Lin
Genentech · 218 works · 5,127 citations · h-index 26
Top works
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- A role for alpha-synuclein in the regulation of dopamine biosynthesis.
- Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non–Small Cell Lung Cancers
- A Role for α-Synuclein in the Regulation of Dopamine Biosynthesis
- Reproducible pharmacogenomic profiling of cancer cell line panels
- Autocrine CSF-1R activation promotes Src-dependent disruption of mammary epithelial architecture
- USP7 small-molecule inhibitors interfere with ubiquitin binding
- Oncogenic Activating Mutations Are Associated with Local Copy Gain
- AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
- Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition
- Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
- An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance
- Regulation of the 75-kDa Subunit of Mitochondrial Complex I by Iron
- Effects of GDNF on 6‐OHDA‐induced death in a dopaminergic cell line: Modulation by inhibitors of PI3 kinase and MEK
- Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
- ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma
- Rapid activation of ERK by 6‐hydroxydopamine promotes survival of dopaminergic cells
- Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors
- ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy
- Machine-Learning and Chemicogenomics Approach Defines and Predicts Cross-Talk of Hippo and MAPK Pathways